RxDoctor Payments Data

Julie Zhong, MD

Family Medicine · Garland, TXNPI 1821559816

Payments from drug & device makers

$2,062in general payments, 2019–2025

Across 88 payments — averaging $23.43 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$200
  • Novo Nordisk$191
  • GSK$186
  • Medtronic$172
  • Bayer$168
  • Lilly USA, LLC$137
  • plus $1K from 18 others

What the payments were for

  • Food & beverage$2,00297%
  • Education$603%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,062 in reported general payments places this provider in the 70th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$83,632
Medicare patients
198
Services billed
1,258

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide40$52,922
OzempicSemaglutide24$23,839
EliquisApixaban13$13,337
JardianceEmpagliflozin13$11,520
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog11$6,729
Lantus SolostarInsulin Glargine,hum.Rec.Anlog23$3,320
SynthroidLevothyroxine Sodium15$1,798
Atorvastatin Calcium168$1,652
Omeprazole67$1,220
Gabapentin72$1,127
Zolmitriptan11$1,070
Losartan Potassium99$1,011
Levothyroxine Sodium132$1,011
Estradiol16$927
Sertraline Hcl65$868

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$137$52,92240 claims
Novo NordiskOzempic$191$23,83924 claims
PfizerEliquis$125$13,33713 claims
Boehringer IngelheimJardiance$58$11,52013 claims
AbbVieSynthroid$137$1,79815 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Garland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →